We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Ebolavirus Found in Semen Months After Symptom Onset

By LabMedica International staff writers
Posted on 04 Nov 2015
The main mode of transmission is direct contact with the blood or body fluids of a person with Ebolavirus disease (EVD) or from the body of a person who died from EVD; however, Ebolavirus can persist in the body fluids of survivors during convalescence, which may result in transmission of the virus.

Previously, survivors of EVD were told to practice sexual abstinence or to use a condom for three months after recovery. More...
These recommendations were based on virus-isolation results from semen specimens obtained from eight survivors of EVD or Marburgvirus disease in previous epidemics in which the longest period that infectious virus was found in semen after the onset of symptoms was 82 days.

A large international team of scientist led by those from the Sierra Leone Ministry of Health (Freetown, Sierra Leone) recruited a convenience sample of 100 male survivors from the Western Area District of Sierra Leone, which includes the capital of Freetown. They identified study participants who, at informational events that were held in conjunction with survivor associations, indicated interest in participation, as well as persons who were referred from Ebola treatment centers. A member of the study team administered a questionnaire to all the participants at the time of enrollment to gather information about their EVD episode, self-reported health status, sexual behavior, and sociodemographic characteristics, and the date of EVD onset was self-reported.

Semen specimens were collected and refrigerated at 5 °C to 8 °C for no longer than three days and transported to the field laboratory. The team performed quantitative reverse transcription polymerase chain reaction (RT-PCR) testing using Ebolavirus–specific gene targets (NP and VP40) and the human β2-microglobulin (B2M) gene. A specimen was considered positive if the VP40 and NP gene targets were both detected within 40 cycles of replication. The specimen was considered to be negative if neither Ebolavirus gene targets were detected nor the findings with respect to B2M status were positive. The findings were ruled to be indeterminate if either the VP40 or the NP gene target was detected but not both. Amplification of B2M served as an extraction control and RNA quality control.

A total of 46 of the 93 men (49%) had a specimen that was positive on quantitative RT-PCR. Ebolavirus RNA was detected in the semen of all 9 men from whom a specimen was obtained during the first three months after the onset of illness, in the semen of 26 of 40 men (65%) from whom a specimen was obtained at four to six months, and in the semen of 11 of 43 men (26%) from whom a specimen was obtained at seven to nine months. The longest time after the onset of a participant’s EVD symptoms that a semen specimen obtained at baseline remained positive on quantitative RT-PCR was 284 days. Indeterminate results were encountered in 10 initial specimens in the range of 152 to 273 days after the onset of symptoms.

Bruce Aylward, MD, an Assistant Director-General at the World Health Organization (Geneva, Switzerland) said, “These results come at a critically important time reminding us that while Ebola case numbers continue to plummet, Ebola survivors and their families continue to struggle with the effects of the disease. This study provides further evidence that survivors need continued, substantial support for the next 6 to12 months to meet these challenges and to ensure their partners are not exposed to potential virus.” The study was published on October 14, 2015, in the New England Journal of Medicine (NEJM).

Related Links:

Sierra Leone Ministry of Health 
World Health Organization 



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.